OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
The organization is working to give oncology professionals the chance to hear directly from patients about their unique experiences, concerns, and hopes.
A leader from Oracle Health Sciences shares insights on how drug development and research pros collaborated to overcome formidable challenges this year.
This month’s collaborations, tech partnerships, new facilities, and other happenings includes news from Flywheel, Medable, Veeva, and other organizations.
According to an expert from the clinical insights company, prejudice in AI can impact patient outcomes as well as the ability to develop effective treatments.
The company has released a survey of cancer doctors; 83% of those polled believe real-world data is crucial to accelerating cancer research and treatment.
Professionals from various corners of the life-sciences field share views on significant challenges of 2021, bright spots, and what to look for in 2022.
While the pandemic saw many trials to shift to decentralized midstream, an expert from the trial tech firm suggests a ground-up design approach is preferable.
A leader from the Decentralized Trials and Research Alliance offers perspective on the tools, technology, and thinking needed to advance clinical research.
The Parkinson’s Progression Markers Initiative, built using Evidation Health’s research platform, aims to triple enrollment and recruit online participants.
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
The healthcare company has gifted $1m to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.
The US Department of Justice has charged a former CFO and a former head of corporate communications for allegedly conducting an insider trading scheme.
Sited in Pennsylvania, the excipients specialist’s new facility reportedly will work toward advancing drug delivery research and boosting speed to market.
According to a leader from Cytoreason, AI isn’t necessarily the best or only tool suited to discover new and novel therapies—it might take a human touch.
According to a leader from the virtual engagement solutions company, gaps in trial communications can be improved with the intelligent use of technology.
A survey on perceptions toward the decentralized clinical trial format, conducted by Climedo, shows the industry is aware of the benefits but faces barriers
The organizations have issued an in-depth look on issues impacting inclusivity, why change is needed, and potential solutions for increasing trial diversity.
An expert from the contract research organization discusses the impact decentralized trials have had on the industry, and how that transformation is likely to continue.
This month’s announcements of awards, expansions, name changes, hires, and other news includes items from CPhI, Almac Group, ICON, and other organizations.
With the release of its new Sight OLO artificial intelligence based blood analyzer, Sight Diagnostics hopes to offer DCTs reliable, easy-to-use testing.
An expert from the decentralized clinical trial solutions provider discusses how the virtual format and technology can help improve study representation.
A leader from the pharmacovigilance solutions firm discusses the ins and outs managing safety documentation and offers advice on how to deal with them.
Leaders from IQVIA and its Q2 Solutions division offer advice on how to deal with mobile teams, home health providers, and other aspects of virtual trials.
Patient data from the clinical solutions company indicates that gains in recruitment of Black participants is outpacing that of patients from other groups.
The biotech firm has presented data from a study that could offer hope to patients with Parkinson’s, Gaucher, Alzheimer’s and other neurodegenerative conditions.
A leader from Sema4, the health intelligence company, explains how progress in genetic testing has helped advance breast cancer detection and prevention.
Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies.
The StudyTeam Diversity Reporting feature is intended to aid sites and sponsors measure their efforts to reach patients from underrepresented communities.
This month’s launches, expanded facilities, partnerships, and other news includes items from Veeva, Hovione, Florence, Medidata, and other notable firms.
According to data released by the company, the majority of study professionals plan to run agile or hybrid trials over the course of the next 12 months.
According to the pharma firm, Saphnelo (anifrolumab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.
The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
The pharma company has completed enrollment of amyotrophic lateral sclerosis patients in its study investigating drugs like verdiperstat, an oral treatment.
During our November 17 webinar Patient-centric solutions, a group of professionals representing a range of perspectives will share ideas and innovations.
The decentralized tech specialist has acquired Digital Artefacts, a research tech firm focused on cognitive, behavioral, and physiological data capture.
After 30 years’ experience, including stints advising top pharma firms, the expert has joined a firm offering tech aimed at elevating patient ID and enrollment.
The group is collaborating with AbbVie, Janssen, Novartis, Pfizer, and UCB to help advance nocturnal scratch as a digital endpoint for atopic dermatitis.
The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.
The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.
The cloud software firm’s Digital Clinical Trials Survey Report reveals that the industry is adapting to challenges caused by COVID-19 and other factors.
An expert from the decentralized study solutions company shares perspectives on the importance of inclusivity and solutions that could improve representation.
During OSP’s November 17 online event, a group of experts will offer insights, advice, and examples of solutions that put patients at the center of studies.
According to a recent survey from Oracle Health Sciences, 97% of trial professionals say newly adopted approaches will stay in use as we move beyond COVID-19.
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.
